Perspectives on the Trypanosoma cruzi-host cell receptor interactions

Chagas disease is caused by the parasite Trypanosoma cruzi. The critical initial event is the interaction of the trypomastigote form of the parasite with host receptors. This review highlights recent observations concerning these interactions. Some of the key receptors considered are those for throm...

Full description

Saved in:
Bibliographic Details
Published in:Parasitology research (1987) 2009-06, Vol.104 (6), p.1251-1260
Main Authors: Villalta, Fernando, Scharfstein, Julio, Ashton, Anthony W, Tyler, Kevin M, Guan, Fangxia, Mukherjee, Shankar, Lima, Maria F, Alvarez, Sandra, Weiss, Louis M, Huang, Huan, Machado, Fabiana S, Tanowitz, Herbert B
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Bradykinin
Chagas disease
Chagas Disease - parasitology
Fundamental and applied biological sciences. Psychology
Galectin-3
General aspects
General aspects and techniques. Study of several systematic groups. Models
Host-Parasite Interactions
Humans
Immunology
Invertebrates
Laminin
Medical Microbiology
Microbiology
Nerve growth factor
Protozoa
Receptors, Cell Surface
Review
Therapeutic applications
Thrombospondin
TrkA protein
Trypanosoma cruzi
Trypanosoma cruzi - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chagas disease is caused by the parasite Trypanosoma cruzi. The critical initial event is the interaction of the trypomastigote form of the parasite with host receptors. This review highlights recent observations concerning these interactions. Some of the key receptors considered are those for thromboxane, bradykinin, and for the nerve growth factor TrKA. Other important receptors such as galectin-3, thrombospondin, and laminin are also discussed. Investigation into the molecular biology and cell biology of host receptors for T. cruzi may provide novel therapeutic targets.
ISSN:0932-0113
1432-1955
DOI:10.1007/s00436-009-1383-3